TY - JOUR
T1 - Association Between hsTnT and NT-proBNP and Peripheral Artery Disease in People with HIV
T2 - A Multicentre Danish Cohort Study
AU - Holtveg, Thomas R.
AU - Reimer Jensen, Anne Marie
AU - Bock, Ask
AU - Suarez-Zdunek, Moises Alberto
AU - Knudsen, Andreas D.
AU - Nordestgaard, Børge G.
AU - Afzal, Shoaib
AU - Benfield, Thomas
AU - Ostrowski, Sisse R.
AU - Biering-Sørensen, Tor
AU - Frikke-Schmidt, Ruth
AU - Nielsen, Susanne D.
N1 - Publisher Copyright:
© 2025 by the authors.
PY - 2025
Y1 - 2025
N2 - People with HIV (PWH) have a high risk of peripheral artery disease (PAD), and high-sensitivity troponin (hsTnT) and NT-pro B-type natriuretic peptide (NT-proBNP) may be useful biomarkers for PAD in PWH. We assessed associations between hsTnT and NT-proBNP and both prevalent PAD and de novo PAD. Adult PWH were examined at baseline and after 2 years. Inclusion criteria were (1) measurements of hsTnT and NT-proBNP at baseline and (2) ankle brachial index (ABI) at baseline for prevalent PAD and both visits for de novo PAD. PAD was defined as ABI ≤ 0.9. We included 1011 PWH, and 88 (8.7%) had PAD at baseline. Among 802 PWH, 29 (3.6%) had de novo PAD at follow-up. A doubling in hsTnT concentration was associated with prevalent PAD with an OR 1.41 (95% CI: 1.02–1.96, p = 0.04) and 1.40 (95% CI: 0.99–1.98, p = 0.055) in a base model and an adjusted model, respectively. High hsTnT was associated with a risk ratio of 3.39 (95% CI: 1.24–9.27, p = 0.02) for de novo PAD in an unadjusted model and 3.44 (95% CI: 0.98–12.10, p = 0.05) after adjustments. NT-proBNP was not associated with PAD. Thus, hsTnT was associated with higher odds of prevalent PAD and increased risk of de novo PAD.
AB - People with HIV (PWH) have a high risk of peripheral artery disease (PAD), and high-sensitivity troponin (hsTnT) and NT-pro B-type natriuretic peptide (NT-proBNP) may be useful biomarkers for PAD in PWH. We assessed associations between hsTnT and NT-proBNP and both prevalent PAD and de novo PAD. Adult PWH were examined at baseline and after 2 years. Inclusion criteria were (1) measurements of hsTnT and NT-proBNP at baseline and (2) ankle brachial index (ABI) at baseline for prevalent PAD and both visits for de novo PAD. PAD was defined as ABI ≤ 0.9. We included 1011 PWH, and 88 (8.7%) had PAD at baseline. Among 802 PWH, 29 (3.6%) had de novo PAD at follow-up. A doubling in hsTnT concentration was associated with prevalent PAD with an OR 1.41 (95% CI: 1.02–1.96, p = 0.04) and 1.40 (95% CI: 0.99–1.98, p = 0.055) in a base model and an adjusted model, respectively. High hsTnT was associated with a risk ratio of 3.39 (95% CI: 1.24–9.27, p = 0.02) for de novo PAD in an unadjusted model and 3.44 (95% CI: 0.98–12.10, p = 0.05) after adjustments. NT-proBNP was not associated with PAD. Thus, hsTnT was associated with higher odds of prevalent PAD and increased risk of de novo PAD.
KW - biomarker
KW - high-sensitivity troponin T
KW - HIV
KW - NT-pro B-type natriuretic peptide
KW - peripheral arterial disease
U2 - 10.3390/biom15030401
DO - 10.3390/biom15030401
M3 - Journal article
C2 - 40149937
AN - SCOPUS:105001123155
SN - 2218-273X
VL - 15
JO - Biomolecules
JF - Biomolecules
IS - 3
M1 - 401
ER -